Table 2 Baseline demographic and disease characteristics *
Patients <65 y | Patients ≥65 y | |||||
|---|---|---|---|---|---|---|
Characteristic | PBO | CANA 100 mg | CANA 300 mg | PBO | CANA 100 mg | CANA 300 mg |
(n = 509) | (n = 674) | (n = 685) | (n = 137) | (n = 159) | (n = 149) | |
Sex, n (%) | ||||||
Male | 263 (51.7) | 327 (48.5) | 327 (47.7) | 71 (51.8) | 81 (50.9) | 77 (51.7) |
Female | 246 (48.3) | 347 (51.5) | 358 (52.3) | 66 (48.2) | 78 (49.1) | 72 (48.3) |
Age, y | 53.0 ± 8.1 | 52.6 ± 8.1 | 52.8 ± 7.8 | 68.7 ± 3.5 | 70.0 ± 3.6 | 69.1 ± 3.5 |
Race, n (%)† | ||||||
White | 358 (70.3) | 455 (67.5) | 482 (70.4) | 112 (81.8) | 136 (85.5) | 128 (85.9) |
Black or African American | 23 (4.5) | 40 (5.9) | 43 (6.3) | 5 (3.6) | 3 (1.9) | 5 (3.4) |
Asian | 75 (14.7) | 99 (14.7) | 92 (13.4) | 7 (5.1) | 4 (2.5) | 8 (5.4) |
Other‡ | 53 (10.4) | 80 (11.9) | 68 (9.9) | 13 (9.5) | 16 (10.1) | 8 (5.4) |
HbA1c, % | 8.1 ± 1.0 | 8.0 ± 0.9 | 8.0 ± 1.0 | 7.8 ± 0.8 | 7.9 ± 0.9 | 7.9 ± 0.9 |
FPG, mmol/L | 9.3 ± 2.2 | 9.4 ± 2.3 | 9.4 ± 2.3 | 9.0 ± 2.1 | 9.6 ± 2.4 | 9.6 ± 2.6 |
Body weight, kg | 90.1 ± 22.3 | 91.0 ± 22.7 | 89.3 ± 22.8 | 86.3 ± 19.4 | 84.6 ± 19.7 | 84.6 ± 17.7 |
BMI, kg/m2 | 32.2 ± 6.7 | 32.7 ± 6.6 | 32.3 ± 6.7 | 30.8 ± 5.0 | 30.8 ± 5.2 | 30.5 ± 5.2 |
Systolic BP, mmHg | 127.4 ± 13.2 | 126.9 ± 12.6 | 127.6 ± 12.6 | 132.7 ± 13.1 | 132.5 ± 12.8 | 134.3 ± 12.5 |
eGFR, mL/min/1.73 m2 | 90.0 ± 19.9 | 90.9 ± 19.0 | 91.3 ± 18.9 | 75.9 ± 15.1 | 77.3 ± 14.6 | 77.4 ± 13.5 |
Duration of diabetes, y | 6.7 ± 5.4 | 6.4 ± 5.2 | 6.7 ± 5.4 | 10.2 ± 7.9 | 10.5 ± 7.0 | 10.8 ± 8.1 |
Patients with cardiac disorders, n (%)§ | 64 (12.6) | 85 (12.6) | 87 (12.7) | 39 (28.5) | 46 (28.9) | 45 (30.2) |
Patients on antihypertensive medications, n (%)|| | 305 (59.9) | 415 (61.6) | 408 (59.6) | 110 (80.3) | 120 (75.5) | 115 (77.2) |